Loading…

Significance of 2-Methoxypropionic Acid Formed from β-Propylene Glycol Monomethyl Ether: Integration of Pharmacokinetic and Developmental Toxicity Assessments in Rabbits

Commercial grade propylene glycol monomethyl ether (PGME), which is composed of > 99.5% α-isomer and < 0.5% β-isomer, has been shown in several studies to have a low potential for developmental toxicity. Nonetheless, questions have been raised about potential human developmental toxicity due t...

Full description

Saved in:
Bibliographic Details
Published in:Toxicological sciences 2003-02, Vol.71 (2), p.217-228
Main Authors: Carney, E. W., Pottenger, L. H., Johnson, K. A., Liberacki, A. B., Tornesi, B., Dryzga, M. D., Hansen, S. C., Breslin, W. J.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Commercial grade propylene glycol monomethyl ether (PGME), which is composed of > 99.5% α-isomer and < 0.5% β-isomer, has been shown in several studies to have a low potential for developmental toxicity. Nonetheless, questions have been raised about potential human developmental toxicity due to β-PGME, because it can be metabolized to 2-methoxypropionic acid (MPA), a compound bearing structural similarity to the teratogen, methoxyacetic acid (MAA). Accordingly, a series of in vivo developmental toxicity, whole embryo culture, and in vivo pharmacokinetic experiments were conducted in New Zealand White rabbits (highly sensitive to these compounds) to better understand the developmental toxicity potential of MPA and the kinetics of its formation from β-PGME. For the in vivo developmental toxicity studies, groups of 20 inseminated rabbits were gavaged with 0, 10, 26, or 78 mg/kg/day of MPA on gestation day (GD) 7–19, followed by fetal evaluation on GD 28. Results with MPA were compared with those of rabbits similarly dosed with 0, 2.5, 7.5, or 15 mg/kg/day of MAA. Developmental toxicity no-observable-effect levels (NOEL) were approximately 10-fold higher for MPA (26 mg/kg/day) than for MAA (2.5 mg/kg/day). Also, the severity of effects caused by MPA was less than that of MAA, and unlike MAA, MPA was not selectively toxic to the fetus. This differential toxicity was also seen in whole embryo cultures of GD 9 rabbit embryos, in which there were no adverse effects of MPA (1.0, 5.0 mM) or its parent compound, β-PGME (0.5, 2.0 mM), but severe dysmorphogenesis in 100% of embryos cultured in 5.0 mM MAA. The pharmacokinetics study showed rapid and complete conversion of β-PGME to MPA, with a relatively long elimination half-life (33–44 h) for MPA. However, peak and AUC concentrations of MPA in blood associated with the MPA LOEL dose of 78 mg/kg/day were 1.3 mM and 52.9 mM-h/l, respectively, suggesting a relatively high threshold based on internal dosimetry. Taken together, these data indicate a negligible risk of developmental toxicity due to MPA formation from the small amounts of β-isomer present in commercial PGME.
ISSN:1096-6080
1096-0929
1096-0929
DOI:10.1093/toxsci/71.2.217